# Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis

> **NCT00477191** · NA · TERMINATED · sponsor: **Massachusetts General Hospital** · enrollment: 18 (actual)

## Conditions studied

- Psoriasis
- Metabolic Syndrome
- Hyperlipidemia
- Obesity
- Hypertension

## Interventions

- **DRUG:** Etanercept

## Key facts

- **NCT ID:** NCT00477191
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-05
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Difficulty in recruitment.
- **Last updated:** 2016-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00477191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00477191, "Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00477191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*